Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 12/20 | 0.37 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
| ▸ | PIM3 | Q86V86 | 11/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 8/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2930097 | 0.92 | BRAF (0.37) | KDRBRAFFGFR2PIM1FYN | |
| SCHEMBL2933652 | 0.88 | BRAF (0.47) | KDRBRAFPIM1FYNPIM3 | |
| SCHEMBL2933030 | 0.83 | BRAF (0.46) | KDRBRAFFYNPIM3PIM2 | |
| SCHEMBL2927174 | 0.80 | BRAF (0.46) | KDRBRAFPIM1FYNPIM3 | |
| Trifluoroacetic Acid SCHEMBL2928813 | 0.79 | KDR (0.51) | KDRFGFR2PIM1FYNPIM3 | |
| SCHEMBL13515288 | 0.77 | KDR (0.56) | KDRBRAFFGFR2PIM1FYN | |
| Trifluoroacetic Acid SCHEMBL2930092 | 0.73 | HDAC4 (0.44) | KDRPIM3 | |
| SCHEMBL2928815 | 0.73 | KDR (0.50) | KDRFGFR2PIM1FYNPIM3 | |
| SCHEMBL2934386 | 0.72 | BRAF (0.48) | KDRBRAFPIM1FYNPIM3 | |
| SCHEMBL2934370 | 0.72 | PIM3 (0.51) | KDRBRAFFYNPIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044051-B1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB PUBL (SE) | 2010-01-27 | — | — | EP | disclosed |
| US-20080039450-A1 | Compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039450-A1 | Compounds | NEK2, CSNK2A3, CSNK2A1 | KDR 3834/4885BRAF 524/4885FGFR2 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.